Compile Data Set for Download or QSAR
maximum 50k data
Found 5033 of ic50 data for polymerid = 336,50007491,50007492
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212110(US9290485, 142)
Affinity DataIC50:  0.0224nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212116(US9290485, 148)
Affinity DataIC50:  0.0300nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212114(US9290485, 146)
Affinity DataIC50:  0.0400nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM211977(US9290485, 9)
Affinity DataIC50:  0.0912nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50582290(CHEMBL5082614 | US20230286958, Example 198)
Affinity DataIC50:  0.100nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212136(US9290485, 168)
Affinity DataIC50:  0.100nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212115(US9290485, 147)
Affinity DataIC50:  0.100nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50582290(CHEMBL5082614 | US20230286958, Example 198)
Affinity DataIC50:  0.100nMAssay Description:Inhibition of human plasma kallikrein using fluorogenic substrate measured by microplate reader analysisMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212004(US9290485, 36)
Affinity DataIC50:  0.134nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50582290(CHEMBL5082614 | US20230286958, Example 198)
Affinity DataIC50:  0.200nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50582291(CHEMBL5078294 | US20230286958, Example 200)
Affinity DataIC50:  0.200nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50582291(CHEMBL5078294 | US20230286958, Example 200)
Affinity DataIC50:  0.200nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50582287(CHEMBL5079850 | US20230286958, Example 41)
Affinity DataIC50:  0.200nMAssay Description:Inhibition of human plasma kallikrein using fluorogenic substrate measured by microplate reader analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50582288(CHEMBL5089406 | US20230286958, Example 136)
Affinity DataIC50:  0.200nMAssay Description:Inhibition of human plasma kallikrein using fluorogenic substrate measured by microplate reader analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50582291(CHEMBL5078294 | US20230286958, Example 200)
Affinity DataIC50:  0.200nMAssay Description:Inhibition of human plasma kallikrein using fluorogenic substrate measured by microplate reader analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212135(US9290485, 167)
Affinity DataIC50:  0.200nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50597231(CHEMBL5201574)
Affinity DataIC50:  0.200nMAssay Description:Inhibition of human plasma kallikrein assessed as substrate hydrolysis using acetyl-K-P-R-AFC as substrate by spectrofluorometric analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50582288(CHEMBL5089406 | US20230286958, Example 136)
Affinity DataIC50:  0.200nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM211974(US9290485, 6)
Affinity DataIC50:  0.200nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212113(US9290485, 145)
Affinity DataIC50:  0.200nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM212134(US9290485, 166)
Affinity DataIC50:  0.200nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50582287(CHEMBL5079850 | US20230286958, Example 41)
Affinity DataIC50:  0.200nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM617989(6-(3-Chloro-6-(difluoromethyl)-2-fluorophenyl)-N-(...)
Affinity DataIC50:  0.300nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM528130(N-{[2-fluoro-3-methoxy-6-(1,2,3,4-tetrazol-1-yl)ph...)
Affinity DataIC50:  0.300nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM617993(6-(3-Chloro-6-(difluoromethyl)-2-fluorophenyl)-N-(...)
Affinity DataIC50:  0.300nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM617993(6-(3-Chloro-6-(difluoromethyl)-2-fluorophenyl)-N-(...)
Affinity DataIC50:  0.300nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM618006(6-(3-Chloro-6-(difluoromethyl)-2-fluorophenyl)-N(1...)
Affinity DataIC50:  0.300nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50574377(CHEMBL4853430)
Affinity DataIC50:  0.300nMAssay Description:Inhibition of human plasma kallikrein using H-Pro-Phe-AMC as fluorogenic substrate measured every 2 mins for 12 mins by microplate reader analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50574379(CHEMBL4875151)
Affinity DataIC50:  0.300nMAssay Description:Inhibition of human plasma kallikrein using H-Pro-Phe-AMC as fluorogenic substrate measured every 2 mins for 12 mins by microplate reader analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50582286(CHEMBL5079924 | US20230286958, Example 45)
Affinity DataIC50:  0.300nMAssay Description:Inhibition of human plasma kallikrein using fluorogenic substrate measured by microplate reader analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50582289(CHEMBL5076760 | US20230286958, Example 155)
Affinity DataIC50:  0.300nMAssay Description:Inhibition of human plasma kallikrein using fluorogenic substrate measured by microplate reader analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM617832(US20230286958, Example 44)
Affinity DataIC50:  0.300nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50597230(CHEMBL5208510)
Affinity DataIC50:  0.300nMAssay Description:Inhibition of human plasma kallikrein assessed as substrate hydrolysis using acetyl-K-P-R-AFC as substrate by spectrofluorometric analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM617940(6-(3-Chloro-6-(difluoromethyl)-2-fluorophenyl)-N-(...)
Affinity DataIC50:  0.300nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50582289(CHEMBL5076760 | US20230286958, Example 155)
Affinity DataIC50:  0.300nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Rattus norvegicus)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM423170(US10501440, Example 2)
Affinity DataIC50:  0.300nMAssay Description:Human KLKB1 (0.01 U/mL; Enzyme Research Laboratories) or rat KLKB1 (0.625 nM; produced in-house) was incubated for 1 h at room temperature with 0.10 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM528122(3-amino-N-{[5-chloro-2-(1,2,3,4-tetrazol-1-yl)phen...)
Affinity DataIC50:  0.300nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM617991(6-(3-Chloro-6-(difluoromethyl)-2-fluorophenyl)-3-(...)
Affinity DataIC50:  0.300nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM263238(5-amino-1-(4-pyrazol-1-ylmethyl-benzyl)-1h-pyrazol...)
Affinity DataIC50:  0.330nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM618017(6-(3-Chloro-6-(difluoromethyl)-2-fluorophenyl)-3-(...)
Affinity DataIC50:  0.370nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM617989(6-(3-Chloro-6-(difluoromethyl)-2-fluorophenyl)-N-(...)
Affinity DataIC50:  0.400nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50574376(CHEMBL4867704)
Affinity DataIC50:  0.400nMAssay Description:Inhibition of human plasma kallikrein using H-Pro-Phe-AMC as fluorogenic substrate measured every 2 mins for 12 mins by microplate reader analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM618014(US20230286958, Example 226)
Affinity DataIC50:  0.400nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM618022(6-(3-Chloro-6-cyano-2-fluorophenyl)-3-methyl-N-(1-...)
Affinity DataIC50:  0.400nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM618028(6-(3-Chloro-6-(difluoromethoxy)-2-fluorophenyl)-3-...)
Affinity DataIC50:  0.400nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50574378(CHEMBL4867424)
Affinity DataIC50:  0.400nMAssay Description:Inhibition of human plasma kallikrein using H-Pro-Phe-AMC as fluorogenic substrate measured every 2 mins for 12 mins by microplate reader analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50574380(CHEMBL4873547)
Affinity DataIC50:  0.400nMAssay Description:Inhibition of human plasma kallikrein using H-Pro-Phe-AMC as fluorogenic substrate measured every 2 mins for 12 mins by microplate reader analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50574381(CHEMBL4854358)
Affinity DataIC50:  0.400nMAssay Description:Inhibition of human plasma kallikrein using H-Pro-Phe-AMC as fluorogenic substrate measured every 2 mins for 12 mins by microplate reader analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM617802(6-(3-Chloro-6-(difluoromethyl)-2-fluorophenyl)-3-m...)
Affinity DataIC50:  0.400nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM617827(US20230286958, Example 39)
Affinity DataIC50:  0.400nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaC12, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 5033 total ) | Next | Last >>
Jump to: